IN SPITE OF THE EVOLUTION of cancer therapy techniques, the prognosis of patients with the diagnosis of uterine sarcomas remains poor. Radiation therapy may be of value when combined with surgery, although it is difficult to prove or disprove since no prospective randomized trial exists. Also, patient selection has taken place in all published series which would presumably bias results in favor of those patients receiving surgery alone. Local control was improved when radiation therapy was added to surgery as shown in this and other studies.
Since distant metastasis is the major avenue of failure, systemic therapy is the chief hope to improve the rather dismal outlook for these patients. National studies currently under way will hopefully define the place of systemic chemotherapy.